Last reviewed · How we verify
NCT06557603
Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream
Phase 1 trial testing Ivermectin cream in Rosacea in 44 participants. Completed in 22 July 2024.
11 July 2024
Quick facts
| Lead sponsor | Humanis Saglık Anonim Sirketi |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 44 |
| Start date | 6 March 2024 |
| Primary completion | 11 July 2024 |
| Estimated completion | 22 July 2024 |
| Sites | 1 location across India |
Drugs / interventions tested
- Ivermectin cream
- Soolantra ® (Ivermectin) cream — full drug profile →
Conditions studied
- Rosacea — all drugs for Rosacea →
Sponsor
Humanis Saglık Anonim Sirketi — full company profile →
Who can join
Adults 18 to 45, any sex, with Rosacea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single dose bioequivalence study of Ivermectin 1% cream and Soolantra (Ivermectin) 10 mg/g cream in healthy adult human subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06557603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivermectin cream
Trials testing the same drug.
- NCT05213585 — Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1% · Phase 1 · unknown
Other recruiting trials for Rosacea
Currently open trials in the same condition.
- NCT07296497 — Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety · NA · recruiting
- NCT06312813 — Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With · Phase 2 · recruiting
- NCT06072066 — Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammatio · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
- NCT05928169 — Determinants of Chronic Inflammatory Skin Disease Trajectories · recruiting
Other Humanis Saglık Anonim Sirketi trials
Trials by the same sponsor.
- NCT07372118 — Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tabl · Phase 1 · completed
- NCT07278349 — Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets · Phase 1 · completed
- NCT07266779 — Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Pr · Phase 1 · completed
- NCT07266766 — Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tabl · Phase 1 · completed
- NCT07266792 — Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpipraz · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06557603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Humanis Saglık Anonim Sirketi
- Last refreshed: 20 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06557603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing